Astellas Pharma Inc (ALPMY)
9.54
+0.07
(+0.74%)
USD |
OTCM |
Apr 25, 16:00
Astellas Pharma Research and Development Expense (Quarterly): 503.80M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 503.80M |
| September 30, 2023 | 535.53M |
| June 30, 2023 | 470.72M |
| March 31, 2023 | 530.53M |
| December 31, 2022 | 474.36M |
| September 30, 2022 | 471.76M |
| June 30, 2022 | 571.15M |
| March 31, 2022 | 588.45M |
| December 31, 2021 | 515.39M |
| September 30, 2021 | 551.90M |
| June 30, 2021 | 532.74M |
| March 31, 2021 | 525.62M |
| December 31, 2020 | 546.91M |
| September 30, 2020 | 512.70M |
| June 30, 2020 | 532.37M |
| March 31, 2020 | 592.01M |
| December 31, 2019 | 503.78M |
| September 30, 2019 | 479.83M |
| June 30, 2019 | 486.83M |
| March 31, 2019 | 533.25M |
| December 31, 2018 | 446.99M |
| September 30, 2018 | 425.55M |
| Date | Value |
|---|---|
| June 30, 2018 | 477.97M |
| March 31, 2018 | 545.74M |
| December 31, 2017 | 479.40M |
| September 30, 2017 | 459.83M |
| June 30, 2017 | 508.32M |
| March 31, 2017 | 526.27M |
| December 31, 2016 | 445.52M |
| September 30, 2016 | 475.31M |
| June 30, 2016 | 472.42M |
| March 31, 2016 | 526.55M |
| December 31, 2015 | 435.93M |
| September 30, 2015 | 458.85M |
| June 30, 2015 | 461.48M |
| March 31, 2015 | 491.77M |
| December 31, 2014 | 445.72M |
| September 30, 2014 | 475.13M |
| June 30, 2014 | 466.38M |
| March 31, 2014 | 514.33M |
| December 31, 2013 | 479.27M |
| September 30, 2013 | 468.47M |
| June 30, 2013 | 446.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
470.72M
Minimum
Jun 2023
592.01M
Maximum
Mar 2020
522.44M
Average
525.62M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 1.269B |
| Nxera Pharma Co Ltd | 20.74M |
| PeptiDream Inc | 6.067M |
| Stemcell Holdings Inc | -- |
| Healios KK | 5.235M |